Increased peroxiredoxin 6 expression predicts biochemical recurrence in prostate cancer patients after radical prostatectomy

Anticancer Research

Volumn 35, Issue 12, 2015, Pages 6465-6470

  Raatikainen, Sami ^a,b   Aaaltomaa, Sirpa ^a   Kärjä, Vesa ^a   Soini, Ylermi ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Peroxiredoxin; Prognosis; Prostate cancer; Radical prostatectomy; Sulfiredoxin

Indexed keywords

OXIDOREDUCTASE; PEROXIREDOXIN 6; SULFIREDOXIN; UNCLASSIFIED DRUG; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BONE SCINTISCANNING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; DEMOGRAPHY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER SPECIFIC SURVIVAL; PROSTATECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL; TRANSRECTAL ULTRASONOGRAPHY; CHEMISTRY; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS;

HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIREDOXIN VI; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84949431606     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Fleshner NE and Lawrentschuk N: Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology 73: S21-7, 2009.
2. Martin NE, Mucci LA, Loda M and Depinho RA: Prognostic determinants in prostate cancer. Cancer J 17: 429-437, 2011.
3. Karihtala P and Soini Y: Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 115: 81-103, 2007.
4. Rhee SG, Yang KS, Kang SW, Woo HA and Chang TS: Controlled elimination of intracellular H(2)O(2): regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxid Redox Signal 7: 619-626, 2005.
5. Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W and Jia WD: Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol 31: 786-013-0786-2.
6. Li J, Yang ZL, Ren X, Zou Q, Yuan Y, Liang L, Chen M and Chen S: ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol 34: 359-368, 2013.
7. Soini Y, Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Kang SW, Tammela TL, Peltoniemi M, Martikainen PM and Kinnula VL: Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma. APMIS 114: 329-337, 2006.
8. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res 9: 3418-3424, 2003.
9. Karihtala P, Soini Y, Vaskivuo L, Bloigu R and Puistola U: DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer 19: 1047-1051, 2009.
10. Valdman A, Haggarth L, Cheng L, Lopez-Beltran A, Montironi R, Ekman P and Egevad L: Expression of redox pathway enzymes in human prostatic tissue. Anal Quant Cytol Histol 31: 367-374, 2009.
11. Whitaker HC, Patel D, Howat WJ, Warren AY, Kay JD, Sangan T, Marioni JC, Mitchell J, Aldridge S, Luxton HJ, Massie C, Lynch AG and Neal DE: Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. Br J Cancer 109: 983-993, 2013.
12. Chaiswing L, Zhong W and Oberley TD: Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression. Free Radic Biol Med 67: 342-352, 2014.
13. Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De Leon M and Casiano CA: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 71: 755-765, 2011.
14. Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G, Sultmann H, Korf U, Bokemeyer C, Walther R, Brummendorf TH and Balabanov S: Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res 11: 2452-2466, 2012.
15. Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T and Naito S: Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Radic Biol Med 51: 78-87, 2011.
16. He HC, Zhu JG, Chen XB, Chen SM, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH and Zhong WD: MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett 586: 2451-2458, 2012.
17. Merikallio H, Paakko P, Kinnula VL, Harju T and Soini Y: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol 43: 577-584, 2012.
18. Wei Q, Jiang H, Matthews CP and Colburn NH: Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proc Natl Acad Sci USA 105: 19738-19743, 2008.
19. Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H and Karakiewicz PI: Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 181: 601-7; discussion 607-8, 2009.
20. Sobin LH, Wittekind C, Gospodarowicz MK and International Union Against Cancer: TNM classification of malignant tumours. Oxford, Wiley-Blackwell, 2010.
21. Epstein JI, Allsbrook WC,Jr, Amin MB, Egevad LL and ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29: 1228-1242, 2005.
22. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B and Manoharan M: Careful selection and close monitoring of lowrisk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 58: 831-835, 2010.
23. Capitanio U, Briganti A, Gallina A, Suardi N, Karakiewicz PI, Montorsi F and Scattoni V: Predictive models before and after radical prostatectomy. Prostate 70: 1371-1378, 2010.
24. Quinn DI, Henshall SM and Sutherland RL: Molecular markers of prostate cancer outcome. Eur J Cancer 41: 858-887, 2005.
25. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F and European Association of Urology: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59: 61-71, 2011.
26. Ouyang X, DeWeese TL, Nelson WG and Abate-Shen C: Lossof-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 65: 6773-6779, 2005.
27. Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D and Chang-Claude J: Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients-potential differential effects by radiotherapy? Breast 22: 817-823, 2013.
28. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ,Jr, Lilja H and Scardino PT: Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24: 3973-3978, 2006.
29. Immenschuh S and Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768-777, 2005.